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Abstract
The efficacy of response to preoperative chemoradiotherapy (CRT) in recurrent
versus primary rectal cancer has not been investigated. We compared radiologi-
cal downsizing between primary and recurrent rectal cancers following CRT
and determined the optimal size reduction threshold for response validated by
survival outcomes. The proportional change in tumor length for primary and
recurrent rectal cancers following CRT was compared using the independent
sample t-test. Overall survival (OS) was calculated using the Kaplan–Meier
product limit method and differences between survival for tumor size reduction
thresholds of 30% (response evaluation criteria in solid tumors [RECIST]),
40%, and 50% after CRT in primary and recurrent rectal cancer groups. A total
of 385 patients undergoing CRT were analyzed, 99 with recurrent rectal cancer
and 286 with primary rectal cancer. The mean proportional reduction in maxi-
mum craniocaudal length was significantly higher for primary rectal tumors
(33%) compared with recurrent rectal cancer (11%) (P < 0.01). There was no
difference in OS for either primary or recurrent rectal cancer when ≤30% or
≤40% definitions were used. However, for both primary and recurrent tumors,
significant differences in median 3-year OS were observed when a RECIST cut-
off of 50% was used. OS was 99% versus 77% in primary and 100% versus
42% in recurrent rectal cancer (P = 0.002 and P = 0.03, respectively). Only
patients that demonstrated >50% size reduction showed a survival benefit.
Recurrent rectal cancer appears radioresistant compared with primary tumors
for tumor size after CRT. Further investigation into improving/intensifying che-
motherapy and radiotherapy for locally recurrent rectal cancer is justified.
Introduction
Improvements in staging and surgical technique have
drastically reduced pelvic recurrence rates in rectal cancer.
However, 3–5% of patients still develop local recurrence
after primary surgery [1, 2] with devastating consequences
such as sacral and perineal pain or obstruction. The med-
ian survival of untreated patients with recurrent rectal
cancer is 3–8 months [3].
The use of preoperative chemoradiotherapy (CRT) and
radiotherapy treatment regimens in recurrent rectal can-
cer have been extrapolated from studies in primary rectal
cancer showing improvements in resectability, local con-
trol, and survival rate [4–7]. However, currently, there are
neither good data from prospective randomized studies
regarding optimum preoperative treatments for recurrent
rectal cancer nor is there data regarding assessing the
efficacy of response to any such treatments. Furthermore,
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there are no comparisons of primary versus recurrent rec-
tal cancer response rates to CRT and therefore whether
extrapolation of dose and regimes are appropriate. Recur-
rent rectal cancer cannot be easily classified using TNM
(Union for International Cancer Control Classification:
Tumor, Node, Metastasis) and studies to date have
provided staging assessments largely based on anatomic
extent [8] and surgical resectability prior to surgical exen-
teration, which cannot easily be measured to judge
response.
Measurement of tumor size is arguably a logical start-
ing point to assess tumor response, but published criteria
to date are subject to controversy and lack outcomes vali-
dation. In 1977, World Health Organization (WHO) pro-
posed a 50% reduction in either bidimensional or
unidimensional measurements as a pragmatic assessment
of tumor response. In later years this was superseded by
response evaluation criteria in solid tumors (RECIST) [9]
1.1 indicating that a >30% reduction in size should be
defined as a partial response. Very few validations exist
for RECIST criteria against outcomes in rectal cancer and
none for recurrent rectal cancer. A recent study evaluating
tumor response in Phase I trials demonstrated that tumor
response could be considered as a continuous variable
that correlates linearly with outcomes [10, 11]. It could
be seen from this data that the standard RECIST 30%
cut-off for response has a tendency to overestimate
responders and that the best outcomes are seen when
response is 45% or more [12, 13]. If a response threshold
can be validated for rectal cancers, then this may better
assist in the objective assessment of response in patients
undergoing treatment for pelvic recurrent disease.
This study attempts to define a clinically meaningful
tumor shrinkage threshold and its corresponding survival
benefit in patients with primary and recurrent rectal can-
cer and to compare any differences in CRT response rates
for these two groups of patients.
These results may enable future studies to evaluate
CRT regimens and radiotherapy doses in patients with
recurrent rectal cancer.
Methods
The project was a cohort analysis of all patients treated
with preoperative CRT at a single institution for either
locally advanced or recurrent rectal cancer between 2003
and 2011. The study protocol was approved as a service
evaluation study by the Local Institutional Ethical and
Research Review Board. As the project was noninterven-
tional, patient consent was not required.
The primary aim of this study was to determine the
difference in radiological downsizing response between
primary locally advanced rectal cancer and local recur-
rent rectal cancer (CRT naı¨ve) following CRT and, sec-
ond, to determine the optimal RECIST threshold for
response validated by survival outcomes. Based on inde-
pendent sample t testing, a sample size of at least 50
patients in each group would be required to detect a
19% (72% [14] vs. 53%) difference in mean reduction
in tumor size following CRT with 80% power.
Preoperative clinical assessment and
treatments
Patients diagnosed with primary rectal cancer and recur-
rent rectal cancer underwent clinical examination, colo-
noscopy, high-resolution MRI pelvis [15], and CT chest,
abdomen, and pelvis (CT CAP) as staging. The clinical,
radiological, and histological results were reviewed in the
multidisciplinary team (MDT) meeting.
For primary tumors, rectal cancer stage was confirmed.
For recurrences, local extent and compartmental
involvement were recorded and a treatment plan was rec-
ommended.
All patients included in this study received CRT using
50.4–54.0 Gy/28–30 fractions with Capecitabine 825 mg/
m2 twice daily during RT.
Reassessment high-resolution MRI and CT CAP scans
were acquired at a minimum of 4 weeks following com-
pletion of CRT and restaged at the MDT meeting prior
to further management. Maximum two-dimensional
craniocaudal lengths of the rectal tumors and recurrent
tumors were measured before and after CRT using high-
resolution MRI.
Histopathology
All specimens were evaluated according to the Royal Col-
lege of Pathologists’ protocol [16]. The specimens were
received fresh, and fixed in 10% formalin. After the speci-
men is fixed, the segments of bowel including the tumor,
the 30 mm segment of intestine proximally and distally
to the tumor, and the attached mesentery were sectioned
transversely at 3–4 mm intervals with a sharp knife to
produce slices that included the tumor, the adjacent
lymph nodes, and the serosal and nonperitonealized
resection margins [16]. Slices were embedded in blocks
and processed for hematoxylin and eosin staining in
5 mm sections. If no definite residual tumor could be
recognized, the whole of the tumor site/scar was blocked
for histology. The ypT category was recorded. Pathologi-
cal complete response (pCR) was defined as the absence
of any tumor cells in pathology specimen defined as
ypT0N0.
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Statistical analysis
The proportional change in tumor size in primary rectal
cancer and local recurrent rectal cancer was compared
using the independent sample t-test.
The proportional change in tumor length before and
after CRT by MRI was compared for the primary rectal and
recurrent rectal cancer groups. The tumor size reduction
was calculated as (baseline—posttreatment craniocaudal
lengths)/baseline craniocaudal length.
Overall survival (OS) was calculated using the Kaplan–
Meier product limit method and differences between sur-
vival for tumor size reduction thresholds of 30% (RE-
CIST) [9], 40%, and 50% after CRT in primary rectal
cancer and recurrent rectal cancer groups. The differences
in survival were tested for significance using the Mantel–
Cox log-rank test.
For patients in the primary rectal cancer and recurrent
rectal cancer group, OS was measured from the date of
diagnosis of primary cancer or recurrent rectal cancer,
respectively, to the date of event, that is, death.
For all analyses, a P-value less than 5% was considered
significant.
Inclusion criteria
Patients with biopsy proven primary rectal cancer who
received neoadjuvant CRT and patients with recurrent
rectal cancer who were CRT naive were included in the
study.
Inclusion criteria were as follows: biopsy-proven pri-
mary rectal cancer patients who had received neoadjuvant
CRT, recurrent rectal cancer patients receiving CRT,
WHO performance status 0–2.
Patients with recurrent rectal cancer were CRT na€ıve
due to stage and clinical reasons at initial presentation.
The clinical reasons why patients had not undergone CRT
and later presented with recurrent rectal cancer were as
follows:
1 Patient choice.
2 Requiring immediate surgery due to emergency.
3 In 2003–2006, MRI was not used to determine the
optimal plane of surgery for abdominoperineal exci-
sion; therefore, there were high rates of positive mar-
gins due to less than optimal surgical planning and the
use of CRT, this has subsequently been addressed in
low rectal cancer trial [17–19].
Exclusion criteria
Patients less than 18 years old.
Received short-course preoperative radiotherapy
(SCPRT) or RT alone.
Did not undergo MRI before and after CRT.
Had incomplete histology data.
Received adjuvant CRT and other malignancy.
Table 1. Patients’ demographics with primary rectal cancer and
recurrent rectal cancer treated with CRT between 2003 and 2009.
Variable
Primary rectal
cancer
Recurrent
rectal cancer
P-
value
Gender Total = 286 Total = 56
Male 176 38
Female 110 18 0.32
Age
>50 43 11
>50 243 45 0.37
Median time
to MRI
29 days (25th
and 75th
percentile:
28–33 days)
30 days (25th
and 75th
percentile:
27–35 days)
Pretreatment tumor
size (MRI staging)
≤4 cm
120 (42%) 32 (57%)
>4 cm 166 (58%) 24 (43%) 0.04
Primary staging T-stage (MR) or original primary tumor stage (for
recurrence)
≤mrT2 119 (42%) 23 (41%)
>mrT2 167 (58%) 33 (59%) 1.00
mrN0 201 (70%) 36 (64%)
mrN1/N2 85 (30%) 20 (36%) 0.43
Primary tumor distance from anal verge (by MRI)
>5 cm 194 (68%) 40 (71%)
≤5 cm 92 (32%) 16 (29%) 0.64
Primary tumor EMVI status by MRI
Negative 247 (86%) 47 (84%)
Positive 39 (14%) 9 (16%) 0.67
Primary tumor CRM status by MRI
Negative 269 (94%) 54 (96%)
Positive 17 (6%) 2 (4%) 0.75
MRI response after CRT (size reduction)
0–30% 137 34
31–49% 79 14
>50% 70 8 0.15
Median 3 years OS in
>30% 82% 49%
≤30% 83% (P = 0.57) 36% (P = 0.28)
>40% 83% 53%
≤40% 81% (P = 0.28) 39% (P = 0.36)
>50% 96% (95%
CI = 90–102%)
100% (95%
CI = 84–116%)
≤50% 77% (95%
CI = 71–83%)
(P = 0.002)
42% (95%
CI = 27–57%)
(P = 0.03)
Site of tumor recurrent
Anastomotic site 18 (32%)
Nonanastomotic site 38 (68%)
CRM, circumferential resection margin; CRT, chemoradiotherapy;
EMVI, extramural vascular invasion; OS, overall survival.
Bold values indicate statistically significant.
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Results
In total, 385 patients with primary or recurrent rectal
cancer who underwent CRT between 2003 and 2011 were
included in the study, 99 of whom had recurrent rectal
cancer and the remaining 286 had primary locally
advanced rectal cancer. A total of 50/286 patients with
primary rectal cancer (17% with 95% CI 11–19%) devel-
oped pCR after CRT. Forty-three patients with recurrent
rectal cancer were excluded from analysis: As a repeat
MRI following CRT was not performed, all these patients
were treated with palliative intent.
Patient demographics and characteristics are shown in
Table 1. The median follow-up period for the cohort was
43 months. There was no significant difference in baseline
characteristics of patients with primary rectal cancer and
those of the original primary rectal cancer prior to pri-
mary surgery/recurrence for recurrent rectal cancer
patients.
The median time for MRI after CRT was 29 days (25th
and 75th percentile: 28–33 days) in patients with primary
rectal cancer and 30 days (25th and 75th percentile: 27–
35 days) in patients with recurrent rectal cancer.
Of the 56 recurrent rectal cancer patients who under-
went CRT, 30 (54%) underwent surgery. Eleven of 30
(37%) patients who underwent surgery had R1 resections
and 19/30 patients (63%) had R0 complete resections.
Five of 56 (9% with 95% CI 2–17%) patients with recur-
rent rectal cancer developed pCR following CRT.
The mean rectal tumor size was significantly larger
(0.58 cm vs. 0.43 cm with P = 0.04) for primary tumor
compared with recurrent tumors. The mean proportional
reduction in maximum craniocaudal length was signifi-
cantly higher for primary rectal tumors (33%) when com-
pared with recurrent rectal cancer (11%) after CRT
(P < 0.01). Hence, recurrent rectal cancer was signifi-
cantly less responsive in terms of tumor size reduction
after CRT when compared with primary rectal cancers.
Survival analysis
There was no difference in OS for either in primary or
recurrent rectal cancer when either a ≤ 30% or ≤40% RE-
CIST definition was used for tumor size reduction after
CRT. However, for both primary and recurrent tumors,
significant differences in median 3-year OS were observed
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Figure 1. Overall survival in patients with primary rectal cancer who underwent chemoradiotherapy (CRT).
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when a RECIST cut-off of 50% was used (P = 0.002 and
P = 0.03, respectively) (Figs. 1 and 2). Patients with pri-
mary rectal cancer who underwent CRT were 2.4 times
more likely (P = 0.03) to develop >50% craniocaudal
length reduction following CRT when compared with
patients with recurrent rectal cancer.
Discussion
Our study has shown that recurrent rectal cancers appear
to be relatively radioresistant compared with primary
rectal cancer and this has not been previously demon-
strated. There was a difference in the rates of pCR
between the primary and recurrent tumor. Although this
has not reached statistical significance, it is interesting to
know that the pCR rate for recurrent cancer was only 9%
(with 95% CI 2–17%), which is substantially lower than
the known published rates for pCR in primary rectal can-
cer. This adds more evidence to our overall findings that
recurrent rectal cancers are relatively chemoradioresistant.
It may therefore be reasonable to question current prac-
tice based on an assumption that response rates to CRT
in recurrent and primary rectal cancer should be equiva-
lent. The commonest CRT regimen used for both recur-
rent and primary rectal cancer is 45–50.4 Gy in 25–28
fractions with fluorouracil (5FU)-based chemotherapy
[20].
Rodel et al. [21] has showed, in a retrospective study
of 35 patients with recurrent rectal cancer, that using
“standard” CRT (50.4 Gy) and 5FU chemotherapy fol-
lowed by extensive curative surgery with R0 resection can
improve the 3 years survival from 39% to 82% when
compared with patients who did not undergo surgery.
Eighty per cent of the recurrent rectal cancer patients
became resectable. Seventeen patients (61%) achieved R0
resection in surgery and patients with R0 resection carried
significant survival benefit. There are few phase I and II
studies investigating into means of intensifying CRT regi-
men in recurrent rectal cancer. Hu et al. [22] showed that
using two cycles of FOLFOX 4 concurrent chemotherapy
(and two to four cycles of FOLFOX 4 after CRT) with
radiotherapy dose of up to 60 Gy in 48 patients with
recurrent tumor carried better survival than RT alone and
the regimen is well tolerated. Caravatta et al. [23] showed
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Figure 2. Overall survival in patients with recurrent rectal cancer who underwent chemoradiotherapy (CRT).
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that using high-dose radiotherapy (55 Gy in 25 fractions)
with oxaliplatin and raltitrexed could be safely adminis-
trated to patients with recurrent rectal cancer. Intra-
operative brachytherapy (IORT) using 10–20 Gy in total,
which has been adopted by some centers for treatment in
recurrent rectal cancer, remains controversial with limited
data regarding benefit and outcomes [24]. For example,
Guo et al. [25] showed that IORT (with a median dose
of 14.4 Gy) was effective in treating recurrent rectal can-
cer. Three years median survival was 43%. Local failure
rate after IORT and surgery was 32%. In contrast, Turley
et al. [26] investigated 29 patients using IORT with a
median dose of 12–15 Gy and showed that 11 patients
(38%) developed long-term morbidity including long-
term wound complication, ureter obstruction, and fistu-
lae. To sum up, CRT with two concurrent chemotherapy
is well tolerated and has better survival rate when com-
pared with RT alone in recurrent rectal cancer and higher
RT dose appears tolerable. Our results have shown that
recurrent rectal cancer is relatively resistant to conven-
tional doses of CRT; therefore, further investigation into
more intensive preoperative treatment for recurrent rectal
cancer is warranted if better radiological response rates
and overall outcomes are to be achieved.
Most staging systems for recurrent rectal cancer to date
have not been shown to be predictive for local control or
OS and there has been no previous agreed definition of
response assessment in recurrent rectal cancer [27]. How-
ever, recent preliminary data suggest that the number of
compartments and the anatomical location of recurrence
are of prognostic relevance [8]. Our study has now shown
that the conventional RECIST definition for response of
30% substantially overestimates the efficacy of response in
terms of overall outcomes. On the other hand, for both
primary and recurrent rectal cancers, a 50% reduction in
size after treatment gives the best prediction for good sur-
vival and is thus the best measure for the effectiveness of
preoperative treatment. This illustrates the importance of
validating response criteria against survival outcomes and
we propose that a craniocaudal length reduction of >50%
after CRT should be considered as an appropriate defini-
tion of “true partial response” for both primary and
recurrent rectal cancer.
A limitation of this study was that response assess-
ment following CRT using MRI was not measured
using mrTumour Regression Grade (mrTRG). More
recently, an mrTRG system has been developed which
predicts survival outcomes and shows good correlation
with histopathology response following preoperative
therapy in primary rectal cancer after CRT [13, 28]. It
is possible that a mrTRG system would also be of prog-
nostic relevance in recurrent rectal cancer, but this
needs to be tested along with our proposed definition
of 50% rather than the conventional 30% “RECIST” in
future studies.
Summary
Locally recurrent rectal cancers have devastating conse-
quences including sacral/perineal pain and obstruction.
Patients with primary and recurrent rectal cancers who
demonstrate a >50% reduction in craniocaudal length fol-
lowing CRT have a survival benefit. Recurrent rectal can-
cer is 2.4 times less likely to show a >50% reduction in
craniocaudal tumor length following CRT. Hence, recur-
rent rectal cancers appear to be relatively radioresistant
compared with primary rectal cancers. Further investiga-
tions into improving clinical relevant staging system,
response assessment, and improving/intensifying chemo-
therapy and radiotherapy response in local recurrent
rectal cancer are much needed.
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